RE: Another RNS1 May 2020 09:30
London, UK., 1 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that it has signed an agreement with a global Japanese pharmaceutical company to evaluate Valirx's therapeutic, VAL301, for the purpose to contemplate a potential future license, for its use in the treatment of endometriosis.
The Material Transfer Agreement ("MTA") covers the evaluation of VAL 301 in a series of preclinical proof of concept and efficacy studies relating to endometriosis. Studies are also scheduled to consider proprietary delivery methods for the compound.
The Japanese Company has already conducted a thorough review of Valirx's prior data under terms of a confidentiality agreement, and now wishes to use material provided by Valirx to conduct their own experiments.
By way of context, ValiRx has developed its VAL301 decapeptide for use in the treatment of endometriosis, while the Japanese Company has a range of pre-clinical assays for testing drug candidates for use in the treatment of endometriosis, as well as several commercial and developmental products in women's health, and other healthcare areas.
To both parties' mutual potential benefit therefore and under the terms of the MTA, ValiRx will supply the required quantities of compound, while the Japanese sponsor will be responsible for undertaking an agreed programme of work at its own expense.
-ENDS-